Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative MPDL3280A in operable bladder transitional cell carcinoma (phase II)
2015-001112-35Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in bladder cancer, sponsored by Queen Mary University of London. Primary endpoint: Pathological complete response rate. Started Sep 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2015-001112-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001112-35.